A Multicenter, Open-label, 8 Day Treatment Study to Assess the Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to <12 Years With Asthma
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 21 Oct 2019 Planned End Date changed from 28 Jan 2020 to 23 Jul 2020.
- 21 Oct 2019 Planned primary completion date changed from 28 Jan 2020 to 23 Jun 2020.
- 21 Oct 2019 Status changed from not yet recruiting to recruiting.